Xilio Therapeutics, Inc.
XLO
$0.67
$0.00640.96%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/17/2025
-
Ticker Report
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)
8/16/2025
-
Simply Wall St
8/14/2025
-
Zacks Investment Research
8/14/2025
-
Fool.com Headlines
8/14/2025
-
The Fly
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
8/14/2025
-
Globe Newswire
8/6/2025
-
GuruFocus
8/6/2025
-
GuruFocus
8/6/2025
-
The Fly
8/4/2025
-
Globe Newswire
8/1/2025
-
GuruFocus
8/1/2025
-
GuruFocus
8/1/2025
-
Globe Newswire
7/2/2025
-
Globe Newswire
6/19/2025
-
MarketBeat
6/12/2025
-
TipRanks Financial Blog
6/10/2025
-
GuruFocus
6/10/2025
-
GuruFocus
6/10/2025
-
TipRanks Financial Blog
6/10/2025
-
Globe Newswire
6/5/2025
-
GuruFocus
6/5/2025
-
GuruFocus
6/5/2025
-
Globe Newswire
6/4/2025
-
Zacks Investment Research
6/3/2025
-
Globe Newswire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 14, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857-524-2466
Address
828 Winter Street
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
Business Description
Sector
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program...
more